• The objective of the Naturelief project is to develop a functional ingredient comprised of botanical extracts
for its use as food supplements.
• It will also design a new digital tool to optimise the consumption of this ingredient and offer a preventive
health solution.
• Monteloeder is leading the execution of this project, which is supported by the Centre for the Development
of Industrial Technology (CDTI) and co-financed with ERDF funds from the European Union.

Work has already begun on the Naturelief R&D project, which will develop a new functional ingredient (based
on botanical extracts to be used in food supplements) as a preventive solution to help manage chronic pain.
Under the title ‘Development of a new functional ingredient of plant origin and digital technology as a
preventive strategy against chronic pain’, this initiative will also design a digital tool to optimise the consumption
and manage the consumer´s journey with the ingredient and, thus, offer a preventive health solution against
chronic pain.

The company Monteloeder is leading this R&D project, which also has the collaboration of various public and
private entities with recognised experience and know-how in the fields covered by this initiative (CIBERSAMUniversity
of Cadiz, ANTALGENICS, IBIDEM, THADERLAB SC, IVAMI, among others).
Naturelief is planned for a duration of 24 months, from 2020 to 2022, divided into two technical-economic
milestones. It has an associated budget of over 600,000 euros, with the support of the CDTI and co-financing
from the European Union’s ERDF funds through Spain’s Multi-regional Operational Programme 2014-2020.
Development and innovation
The innovation proposed by Naturelief is based on the selection of natural active ingredients from plants that
can act on the various pain targets in the human body. In this way, it plans to identify the most effective active
compounds and formulate a new ingredient to help prevent chronic pain issues. In addition, the project
envisages the development of a new digital technology that can be used both for a more complete evaluation
of the efficacy of the ingredient in the clinical study, and subsequently to offer an optimal and personalised
experience to consumers of the functional ingredient.

The development of this new functional ingredient also aims to meet a clear need of the current market,
which demands a natural product that can be consumed on a regular and prolonged basis. It will also be
supported by strong scientific and clinical evidence and be used as a complementary strategy to the use of
drugs and other treatment techniques. In this way, it is expected to alleviate the suffering of chronic pain and
reduce dependence on pharmacological or other treatments.
On the other hand, the application of digital technologies in the development of clinical studies will make it
possible to obtain information from participants, remotely and continuously, in their natural living environment.
This will make it possible to obtain a greater amount of data in order to, through machine learning techniques,
obtain more information on the effect of the product and, subsequently, to have a mobile application for
managing habits related to chronic pain and based on the user’s experience with the product.

About Naturelief:
Naturelief is an R&D project working on the development of a plant-based functional ingredient and the
application of digital technology to establish a preventive strategy against chronic pain. The Alicante-based
company Monteloeder is leading this R&D project in which various public and private entities with recognised
experience and know-how in the fields covered by Naturelief, such as CIBERSAM-University of Cadiz,
ANTALGENICS, IBIDEM, THADERLAB SC, IVAMI, among others, are also collaborating.
The initiative has a budget of 625,342 euros and is supported by the Centre for the Development of Industrial
Technology (CDTI) and co-financed by the European Union’s ERDF funds through Spain’s Pluri-regional
Operational Programme 2014-2020. It is planned with a duration of 24 months, comprised between 2020
and 2022.

For more information, please contact:
andresorts@monteloeder.com